Neurociencia del consumo y dependencia de sustancias psicoactivas
Neurociencia del consumo y dependencia de sustancias psicoactivas Neurociencia del consumo y dependencia de sustancias psicoactivas
6. TRASTORNOS CONCURRENTESdepression. American Journal of Psychiatry, 141:525–529.Ferry LH, Burchette RJ (1994) Evaluation of buproprion versus placebo fortreatment of nicotine dependence. In: American Psychiatric Association NewResearch, Washington, DC, EE.UU. American Psychiatric Press:199–200.Finch DM (1996) Neurophysiology of converging synaptic inputs from the ratprefrontal cortex, amygdala, midline thalamus, and hippocampal formation ontosingle neurons of the caudate/putamen and nucleus accumbens. Hippocampus,6:495–512.Freedman R y colab. (1997) Linkage of a neurophysiological deficit in schizophreniato a chromosome 15 locus. Proceedings of the National Academy ofSciences of the United States of America, 94:587–592.Frye MA y colab. (2003) Gender differences in prevalence, risk, and clinical correlatesof alcoholism comorbidity in bipolar disorder. American Journal ofPsychiatry, 160:883-889.Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse,human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine,and ibogaine. Journal of Pharmacology and Experimental Therapeutics,288:88–92.Fu Y y colab. (2000) Systemic nicotine stimulates dopamine release in nucleusaccumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in theventral tegmental area. Journal of Pharmacology and Experimental Therapeutics,294:458–465.Funahashi S, Kubota K (1994) Working memory and prefrontal cortex.Neuroscience Research, 21:1–11.Gawin FH, Kleber HD (1986) Abstinence symptomatology and psychiatricdiagnosis in cocaine abusers: clinical observations. Archives of General Psychiatry,43:107–113.George TP y colab. (1995) Effects of clozapine on smoking in chronic schizophrenicoutpatients. Journal of Clinical Psychiatry, 56:344–346.George TP y colab. (2000) Nicotine transdermal patch and atypical antipsychoticmedications for smoking cessation in schizophrenia. American Journal ofPsychiatry, 157:1835–1842.George TP y colab. (2002) Effects of smoking abstinence on visuospatial workingmemory function in schizophrenia. Neuropsychopharmacology, 26:75–85.Gerding LB y colab. (1999) Alcohol dependence and hospitalization in schizophrenia.Schizophrenia Research, 38:71–75.Geyer MA, Markou A (1995) Animal models of psychiatric disorders. In: BloomFE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. NuevaYork, NY, EE.UU. Raven Press:787–798.Geyer MA, Markou A (2002) The role of preclinical models in the developmentof psychotropic drugs. en: Charney D y colab., eds. Psychopharmacology: the fifthgeneration of progress. Hagerstown, MD: Lippincott, Williams yWilkins:445–455.Gheorvassaki EG y colab. (1992) Effects of acute and chronic desipramine treatmenton somatostatin receptors in brain. Psychopharmacology, 108:363–366.195
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASGioanni Y y colab. (1999) Nicotinic receptors in the rat prefrontal cortex:increase in glutamate release and facilitation of mediodorsal thalamo-corticaltransmission. European Journal of Neuroscience, 11:18–30.Glassman AH (1993) Cigarette smoking: implications for psychiatric illness.American Journal of Psychiatry, 150:546–553.Glassman AH y colab. (1988) Heavy smokers, smoking cessation, and clonidine:results of a double-blind, randomized trial. Journal of the American MedicalAssociation, 259:2863–2866.Glassman AH y colab. (1990) Smoking, smoking cessation, and major depression.Journal of the American Medical Association, 264:1546–1549.Glynn SM, Sussman S (1990) Why patients smoke. Hospital and CommunityPsychiatry, 41:1027–1028.Goeders NE, Bienvenu OJ, de Souza EB (1990) Chronic cocaine administrationalters corticotropin-releasing factor receptors in the rat brain. Brain Research,531:322–328.Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia:relationship to psychopathology and medication side effects. American Journal ofPsychiatry, 149:1189–1194.Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron, 14:477–485.Gonzalez P y colab. (1997) Decrease of tolerance to, and physical dependenceon, morphine by glutamate receptor antagonists. European Journal ofPharmacology, 332:257–262.Goodwin DW (1992) Alcohol: clinical aspects. En: Lowinson JH y colab., eds.Substance abuse: a comprehensive textbook, 2a edición. Baltimore, MD, EE.UU.Williams y Wilkins:144–151.Grace AA (1995) The tonic/phasic model of dopamine system regulation: its relevancefor understanding how stimulant abuse can alter basal ganglia function.Drug and Alcohol Dependence, 37:111–129.Gray R y colab. (1996) Hippocampal synaptic transmission enhanced by lowconcentrations of nicotine. Nature, 383:713–716.Green AI y colab. (1999) Clozapine for comorbid substance use disorder andschizophrenia: do patients with schizophrenia have a reward-deficiency syndromethat can be ameliorated by clozapine? Harvard Review of Psychiatry,6:287–296.Green AR (1987) Evolving concepts on the interactions between antidepressanttreatments and monoamine neurotransmitters. Neuropharmacology, 26:815–822.Griffith JD y colab. (1972) Dextroamphetamine: evaluation of psychotomimeticproperties in man. Archives of General Psychiatry, 26:97–100.Grillner P, Svensson TH (2000) Nicotine-induced excitation of mid-braindopamine neurons in vitro involves ionotropic glutamate receptor activation.Synapse, 38:1–9.Haertzen CA, Hooks NT Jr (1969) Changes in personality and subjective experienceassociated with the chronic administration and withdrawal of opiates.Journal of Nervous and Mental Disorders, 148:606–614.196
- Page 166 and 167: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 168 and 169: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 170 and 171: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 172 and 173: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 174 and 175: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 176 and 177: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 178 and 179: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 180 and 181: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 182 and 183: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 184 and 185: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 186 and 187: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 188 and 189: 5. BASES GENÉTICAS DE LAS FARMACOD
- Page 190 and 191: Capítulo 6Trastornos ConcurrentesI
- Page 192 and 193: 6. TRASTORNOS CONCURRENTES3. El uso
- Page 194 and 195: 6. TRASTORNOS CONCURRENTESy Meador-
- Page 196 and 197: 6. TRASTORNOS CONCURRENTESprobablem
- Page 198 and 199: 6. TRASTORNOS CONCURRENTESde drogas
- Page 200 and 201: 6. TRASTORNOS CONCURRENTESy Turski,
- Page 202 and 203: 6. TRASTORNOS CONCURRENTESEl víncu
- Page 204 and 205: 6. TRASTORNOS CONCURRENTESAlcohol y
- Page 206 and 207: 6. TRASTORNOS CONCURRENTESSerotonin
- Page 208 and 209: 6. TRASTORNOS CONCURRENTESFunción
- Page 210 and 211: 6. TRASTORNOS CONCURRENTESRECUADRO
- Page 212 and 213: 6. TRASTORNOS CONCURRENTEStos psiqu
- Page 214 and 215: 6. TRASTORNOS CONCURRENTESCarol G y
- Page 218 and 219: 6. TRASTORNOS CONCURRENTESHall RG y
- Page 220 and 221: 6. TRASTORNOS CONCURRENTESKapur S,
- Page 222 and 223: 6. TRASTORNOS CONCURRENTESMansvelde
- Page 224 and 225: 6. TRASTORNOS CONCURRENTESPetty F (
- Page 226 and 227: 6. TRASTORNOS CONCURRENTESSevy S y
- Page 228: 6. TRASTORNOS CONCURRENTESlesions o
- Page 231 and 232: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 233 and 234: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 235 and 236: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 237 and 238: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 239 and 240: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 241 and 242: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 243 and 244: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 245 and 246: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 247 and 248: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 249 and 250: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 251 and 252: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 253 and 254: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 255 and 256: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 257 and 258: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 259 and 260: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 261 and 262: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 263 and 264: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
- Page 265 and 266: NEUROCIENCIA DEL CONSUMO Y DEPENDEN
NEUROCIENCIA DEL CONSUMO Y DEPENDENCIA DE SUSTANCIAS PSICOACTIVASGioanni Y y colab. (1999) Nicotinic receptors in the rat prefrontal cortex:increase in glutamate release and facilitation of mediodorsal thalamo-corticaltransmission. European Journal of Neuroscience, 11:18–30.Glassman AH (1993) Cigarette smoking: implications for psychiatric illness.American Journal of Psychiatry, 150:546–553.Glassman AH y colab. (1988) Heavy smokers, smoking cessation, and clonidine:results of a double-blind, randomized trial. Journal of the American MedicalAssociation, 259:2863–2866.Glassman AH y colab. (1990) Smoking, smoking cessation, and major <strong>de</strong>pression.Journal of the American Medical Association, 264:1546–1549.Glynn SM, Sussman S (1990) Why patients smoke. Hospital and CommunityPsychiatry, 41:1027–1028.Goe<strong>de</strong>rs NE, Bienvenu OJ, <strong>de</strong> Souza EB (1990) Chronic cocaine administrationalters corticotropin-releasing factor receptors in the rat brain. Brain Research,531:322–328.Goff DC, Hen<strong>de</strong>rson DC, Amico E (1992) Cigarette smoking in schizophrenia:relationship to psychopathology and medication si<strong>de</strong> effects. American Journal ofPsychiatry, 149:1189–1194.Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron, 14:477–485.Gonzalez P y colab. (1997) Decrease of tolerance to, and physical <strong>de</strong>pen<strong>de</strong>nceon, morphine by glutamate receptor antagonists. European Journal ofPharmacology, 332:257–262.Goodwin DW (1992) Alcohol: clinical aspects. En: Lowinson JH y colab., eds.Substance abuse: a comprehensive textbook, 2a edición. Baltimore, MD, EE.UU.Williams y Wilkins:144–151.Grace AA (1995) The tonic/phasic mo<strong><strong>de</strong>l</strong> of dopamine system regulation: its relevancefor un<strong>de</strong>rstanding how stimulant abuse can alter basal ganglia function.Drug and Alcohol Depen<strong>de</strong>nce, 37:111–129.Gray R y colab. (1996) Hippocampal synaptic transmission enhanced by lowconcentrations of nicotine. Nature, 383:713–716.Green AI y colab. (1999) Clozapine for comorbid substance use disor<strong>de</strong>r andschizophrenia: do patients with schizophrenia have a reward-<strong>de</strong>ficiency syndromethat can be ameliorated by clozapine? Harvard Review of Psychiatry,6:287–296.Green AR (1987) Evolving concepts on the interactions between anti<strong>de</strong>pressanttreatments and monoamine neurotransmitters. Neuropharmacology, 26:815–822.Griffith JD y colab. (1972) Dextroamphetamine: evaluation of psychotomimeticproperties in man. Archives of General Psychiatry, 26:97–100.Grillner P, Svensson TH (2000) Nicotine-induced excitation of mid-braindopamine neurons in vitro involves ionotropic glutamate receptor activation.Synapse, 38:1–9.Haertzen CA, Hooks NT Jr (1969) Changes in personality and subjective experienceassociated with the chronic administration and withdrawal of opiates.Journal of Nervous and Mental Disor<strong>de</strong>rs, 148:606–614.196
Change language